Classics in Chemical Neuroscience: Pramipexole.,ACS Chemical Neuroscience

当前位置： X-MOL 学术 › ACS Chem. Neurosci. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Classics in Chemical Neuroscience: Pramipexole.
ACS Chemical Neuroscience ( IF 4.1 ) Pub Date : 2020-07-29 , DOI: 10.1021/acschemneuro.0c00332
Sean M Wilson ₁ , Madeline G Wurst ₁ , Michael F Whatley ₁ , R Nathan Daniels _{1,

2}

Affiliation

Pramipexole was first manufactured by Pharmacia and Upjohn in July 1997 under the United States brand names of Mirapex and Mirapex ER. Pramipexole is classified as a nonergoline aminobenzothiazole compound that selectively agonizes the dopamine D₂-like receptor subfamily, which includes the D₂, D₃, and D₄ receptor subtypes. Pramipexole is a unique compound in its therapeutic potential because it has D₃-preferring properties. The D₃ receptor target has implications in both motor and psychiatric symptoms of Parkinson’s disease, restless leg syndrome, and bipolar and unipolar depression. Currently, pramipexole is approved to treat signs and symptoms of idiopathic Parkinson’s disease and moderate to severe symptoms of primary restless leg syndrome. Parkinson’s disease is characterized by tremor, bradykinesia, rigidity, gait disorders, and a disturbance of posture due to a decrease in dopamine stores in the substantia nigra with the consequent presence of Lewy bodies. Restless leg syndrome is a neurologic sensorimotor disorder characterized by a compelling urge to move the body/limb to relieve this uncomfortable sensation. In this Review, we will discuss the synthesis, drug metabolism, pharmacology, adverse effects, history, and the importance of pramipexole to neuroscience and describe its role in therapy.

中文翻译：

化学神经科学经典著作：普拉克索。

普拉克索最初由Pharmacia和Upjohn于1997年7月制造，其美国品牌为Mirapex和Mirapex ER。普拉克索被归类为非麦角灵氨基苯并噻唑化合物，该化合物选择性激动多巴胺D ₂样受体亚家族，其中包括D ₂，D ₃和D ₄受体亚型。普拉克索由于具有D _3-优先特性，因此具有独特的治疗潜力。D ₃受体靶点对帕金森氏病，不安腿综合征，双相和单相抑郁症的运动和精神症状都有影响。目前，普拉克索被批准用于治疗特发性帕金森氏病的症状和体征以及原发性躁动综合征的中重度症状。帕金森氏病的特征是震颤，运动迟缓，僵硬，步态障碍和姿势紊乱，这是由于黑质中多巴胺存储量减少而导致的路易体的存在。腿不安综合症是一种神经系统的感觉运动障碍，其特征在于强烈地促使其移动身体/肢体以减轻这种不适感。在这篇评论中，我们将讨论合成，药物代谢，药理学，不良反应，病史，

更新日期：2020-09-02

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11